Free Trial
NASDAQ:MTSR

Metsera (MTSR) Stock Price, News & Analysis

Metsera logo
$27.59 -0.42 (-1.50%)
As of 04:00 PM Eastern

About Metsera Stock (NASDAQ:MTSR)

Key Stats

Today's Range
$27.00
$28.60
50-Day Range
$13.08
$30.07
52-Week Range
$12.30
$32.81
Volume
778,022 shs
Average Volume
886,447 shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.00
Consensus Rating
Buy

Company Overview

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Receive MTSR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Metsera and its competitors with MarketBeat's FREE daily newsletter.

MTSR Stock News Headlines

Cantor Fitzgerald maintains overweight on Metsera shares
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
Metsera Rings the Opening Bell
See More Headlines

MTSR Stock Analysis - Frequently Asked Questions

Metsera's stock was trading at $29.50 on January 1st, 2025. Since then, MTSR shares have decreased by 7.3% and is now trading at $27.34.
View the best growth stocks for 2025 here
.

Metsera, Inc. (NASDAQ:MTSR) released its earnings results on Monday, May, 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.

Metsera (MTSR) raised $275 million in an IPO on Friday, January 31st 2025. The company issued 15,277,778 shares at $18.00 per share.

Metsera's lock-up period expires on Wednesday, July 30th. Metsera had issued 15,277,778 shares in its IPO on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. After the end of Metsera's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Top institutional shareholders of Metsera include Alphabet Inc. (4.72%), T. Rowe Price Investment Management Inc. (2.75%), Wellington Management Group LLP (2.29%) and Alpha Wave Global LP (2.27%).

Shares of MTSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/12/2025
Today
5/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MTSR
Previous Symbol
NASDAQ:MTSR
Web
N/A
Fax
N/A
Employees
81
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$47.00
High Stock Price Target
$56.00
Low Stock Price Target
$38.00
Potential Upside/Downside
+70.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$2.90 billion
Optionable
N/A
Beta
N/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:MTSR) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners